MNPR
Monopar Therapeutics Health Care Pharmaceutical Preparations Russell 3000
$70.32Close
$470.6MMarket cap
$50.12 – $123.8452-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 29 · weaker than 71% of stocks over 12 months
- Far from its high 43% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
43%
1wk
down 0.5%
price change
1mo
down 11.7%
price change
12-month return
down 18%
market up 11% ·
its own down 27%
F-score
—
— Not assessed
Altman Z
97.59
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.4×
price / book
Earnings yield
down 4.1%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 14%
return on equity
Free cash margin
—
-$12.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.7%
$4.02 a day · 2×ATR $62.28
RS
29 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
1.3×
vs 50-day average
Up/down volume
0.62
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 9.7% over the year, from 6m to 7m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026-4% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $0 |
| Operating income | -$6.5M | -$9.1M | -$10.5M | -$8.8M | -$16.2M | -$16.7M |
| Net income | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| Earnings per share | — | -$0.73 | -$0.83 | -$3.04 | -$4.11 | -$1.85 |
| Free cash flow | -$4.7M | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Cash | $16.7M | $20.3M | $8.2M | $7.3M | $45.8M | $61.8M |
| Shareholders' equity | $15.7M | $18.9M | $10.1M | $5.6M | $55.0M | $137.8M |
| Shares outstanding | 11.45m | 12.60m | 12.95m | 2.98m | 6.10m | 6.69m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 27, 2026 | Annual ↗ | Dec 31, 2025 | 86d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 31, 2025 | Annual ↗ | Dec 31, 2024 | 90d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 12, 2026 | Results ↗ |
| Jul 22, 2026 | Regulation FD ↗ |
| Jun 30, 2026 | Regulation FD ↗ |
| Jun 26, 2026 | Regulation FD ↗ |
| Jun 23, 2026 | Shareholder vote ↗ |
| May 29, 2026 | Regulation FD ↗ |
| May 19, 2026 | Regulation FD ↗ |
| May 14, 2026 | Results ↗ |
| Apr 20, 2026 | Regulation FD ↗ |
| Mar 27, 2026 | Results ↗ |
| Mar 2, 2026 | Regulation FD ↗ |
| Nov 13, 2025 | Results ↗ |